Evidence map›Paper›PMID 35781326›Full record

ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2022

Non-immune and immune functions of interleukin-36γ suppress epithelial repair at the ocular surface.

Sachin Shukla, Won Kyung Cho, Elsayed Elbasiony, Rohan B Singh, Sharad K Mittal, Sunil K Chauhan

Open access · greenAbstract read
In one paragraph

Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Mesenchymal stromal cells protect tissues from Th1 immune responses via IL-11 secretion.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2024
    Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 3 countries.

Sachin ShuklaSchepens Eye Research Institute of Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts, USA.
Won Kyung ChoSchepens Eye Research Institute of Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts, USA.
Elsayed ElbasionySchepens Eye Research Institute of Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts, USA.
Rohan B SinghSchepens Eye Research Institute of Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts, USA.
Sharad K MittalSchepens Eye Research Institute of Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts, USA.
Sunil K ChauhanSchepens Eye Research Institute of Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts, USA.
Harvard University · USMassachusetts Eye and Ear Infirmary · US

Funding

VISION RESEARCHP30EY003790 · NEI · SCHEPENS EYE RESEARCH INSTITUTE · PI Patricia Ann D'Amore · 1985 to 2026
$25.5M
Ocular Immune Regulation by Mesenchymal Stem CellsR01EY024602 · NEI · SCHEPENS EYE RESEARCH INSTITUTE · PI CHAUHAN, SUNIL K · 2015 to 2025
$6.5M
Contribution of Mast Cells in Non-Allergic Ocular InflammationR01EY029727 · NEI · SCHEPENS EYE RESEARCH INSTITUTE · PI Sunil K Chauhan · 2019 to 2026
$4.2M
NEI NIH HHS P30 EY003790NEI NIH HHS R01 EY024602NEI NIH HHS R01 EY029727
6 · The paper itself

Abstract

Regulation of innate inflammation is critical for maintaining tissue homeostasis and barrier function, especially in those interfacing the external environments such as the skin and cornea. Expression of pro-inflammatory cytokines by injured tissues has been shown to exacerbate the inflammatory cascade, causing tissue damage. Interleukin 36, a subfamily of the IL-1 superfamily, consists of three pro-inflammatory agonists-IL36α, IL36β, and IL36γ and an IL36 receptor antagonist (IL36Ra). The current investigation, for the first time, reports that IL36γ is the primary agonist expressed by the corneal epithelium, which is significantly upregulated following corneal injury. The function of IL36γ on non-immune cells, in addition to innate inflammatory cells, in regulating tissue homeostasis has not been well investigated. Using a loss-of-function approach via neutralizing antibody treatment, our data demonstrate that blocking endogenously expressed IL36γ in epithelial cells promotes rapid re-epithelialization in in vitro wound closure assay. Finally, by utilizing a naturally occurring antagonist IL36Ra in a well-established murine model of ocular injury, our study demonstrates that inhibition of IL36γ accelerates epithelial regeneration and suppresses tissue inflammation. Given rapid wound healing is critical for re-establishing normal tissue structure and function, our investigation on the function of IL36γ provides evidence for the development of novel IL36γ-targeting strategies to promote tissue repair.

Indexed as

AnimalsCorneaEpithelium, CornealInflammationInterleukin-1MiceWound HealingIL1F9 protein, mouseInterleukin-1epitheliuminnate inflammationinterleukin 36interleukin 36γ blockadetissue injurytissue regeneration

Identifiers

PMID35781326
PMCPMC9924024
OpenAlexW4283801792

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.